Cargando…
Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine
In recent years, numerous pathways were explored in the pathogenesis of COPD in the quest for new potential therapeutic targets for more personalised medical care. In this context, the study of the cystic fibrosis transmembrane conductance regulator (CFTR) began to gain importance, especially since...
Autores principales: | Carrasco-Hernández, Laura, Quintana-Gallego, Esther, Calero, Carmen, Reinoso-Arija, Rocío, Ruiz-Duque, Borja, López-Campos, José Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533244/ https://www.ncbi.nlm.nih.gov/pubmed/34680554 http://dx.doi.org/10.3390/biomedicines9101437 |
Ejemplares similares
-
Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies
por: López-Campos, Jose Luis, et al.
Publicado: (2021) -
Methodologies for the Determination of Blood Alpha1 Antitrypsin Levels: A Systematic Review
por: Ruiz-Duque, Borja, et al.
Publicado: (2021) -
Acquired cystic fibrosis transmembrane conductance regulator dysfunction
por: Banks, Catherine, et al.
Publicado: (2018) -
Resultados de la implementación de un programa de detección de casos de déficit de alfa-1 antitripsina en pacientes con EPOC
por: Reinoso-Arija, Rocío, et al.
Publicado: (2023) -
Cystic fibrosis transmembrane conductance regulator
mutations at a referral center for cystic fibrosis
por: Coutinho, Cyntia Arivabeni de Araújo Correia, et al.
Publicado: (2013)